Comparative Pharmacology
Head-to-head clinical analysis: MONOKET versus NITROMIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONOKET versus NITROMIST.
MONOKET vs NITROMIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular cGMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing cGMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator